DWP 14012Alternative Names: DWP14012
Latest Information Update: 06 May 2016
At a glance
- Originator Daewoong Pharmaceutical
- Class Antiulcers; Gastric antisecretories
- Mechanism of Action Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Peptic ulcer
Most Recent Events
- 01 Mar 2016 Phase-I clinical trials in Peptic ulcer (In volunteers) in South Korea (PO) (NCT02757144)